Overview

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to establish the objective response rate (complete response + partial response), following treatment with Alimta plus VELCADE, Alimta alone, or VELCADE alone in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have failed prior preventative therapy for Stage IIIb/IV NSCLC. The Alimta alone treatment group will be used as the control. The VELCADE single-agent treatment group will be used to determine if VELCADE administered weekly can demonstrate response rates.

Phase:

Phase 2

Details

Lead Sponsor:

Millennium Pharmaceuticals, Inc.

Collaborator:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Treatments:

Bortezomib
Pemetrexed